Objective:To explore the alteration of irisin in chronic obstructive pulmonary disease(COPD)patients before and after pulmonary rehabilitation(PR)treatment and to analyze the prognostic value of irisin in COPD pa-tients with acute exacerbations.Method:A total of 68 COPD outpatients from department of respiratory and critical care medicine in the Sec-ond Hospital of Hebei Medical University from February 2022 to August 2022 were enrolled and 35 healthy participants were admitted as controls.ELISA was applied to detect the expression of irisin in the serum of the patients.The difference between the COPD group and the health control group and the difference between before and after PR treatment were compared.The correlation analysis was used to analyze the relationship be-tween irisin and 6MWD(6 minutes walking distance)and IL-6(interleukin-6).In addition,K-M survival curve was used to differ the one-year cumulative risk of acute exacerbation-free risk ratio between the low irisin and the high irisin expression group.Result:①The expression of irisin in serum of the COPD patients and the health control group were(16.79±5.83)ng/ml and(34.89±8.68)ng/ml,respectively(P<0.05,t=12.55).②The concentration of irisin in the COPD patients before and after 8 weeks of PR treatment were(17.72±4.56)ng/ml and(19.55±4.25)ng/ml(P<0.05,t=4.43),respectively.③The level of Irisin in the COPD patients was positively correlated with the 6MWD(R=0.475,P<0.05)and negatively related with IL-16 level(R=﹣0.39,P<0.05).④K-M survival curve demonstrated that the median time without AECOPD(acute exacerbations of chronic obstructive pulmo-nary disease)in the low-level irisin and high-level irisin groups were(6.17±0.68)month and(9.58±0.82)month,respectively.Moreover,the cumulative acute exacerbation-free rate in 1 year was 30.0%and 68.12%,respectively(F=11.1 P<0.05).Conclusion:The expression of irisin in serum of the COPD patients was lower than that in the health control group and its level increased after PR treatment.The reduction of irisin might be a poor prognostic indicator for acute exacerbation in patients with COPD.

Objective:To explore the alteration of irisin in chronic obstructive pulmonary disease(COPD)patients before and after pulmonary rehabilitation(PR)treatment and to analyze the prognostic value of irisin in COPD pa-tients with acute exacerbations.Method:A total of 68 COPD outpatients from department of respiratory and critical care medicine in the Sec-ond Hospital of Hebei Medical University from February 2022 to August 2022 were enrolled and 35 healthy participants were admitted as controls.ELISA was applied to detect the expression of irisin in the serum of the patients.The difference between the COPD group and the health control group and the difference between before and after PR treatment were compared.The correlation analysis was used to analyze the relationship be-tween irisin and 6MWD(6 minutes walking distance)and IL-6(interleukin-6).In addition,K-M survival curve was used to differ the one-year cumulative risk of acute exacerbation-free risk ratio between the low irisin and the high irisin expression group.Result:①The expression of irisin in serum of the COPD patients and the health control group were(16.79±5.83)ng/ml and(34.89±8.68)ng/ml,respectively(P<0.05,t=12.55).②The concentration of irisin in the COPD patients before and after 8 weeks of PR treatment were(17.72±4.56)ng/ml and(19.55±4.25)ng/ml(P<0.05,t=4.43),respectively.③The level of Irisin in the COPD patients was positively correlated with the 6MWD(R=0.475,P<0.05)and negatively related with IL-16 level(R=﹣0.39,P<0.05).④K-M survival curve demonstrated that the median time without AECOPD(acute exacerbations of chronic obstructive pulmo-nary disease)in the low-level irisin and high-level irisin groups were(6.17±0.68)month and(9.58±0.82)month,respectively.Moreover,the cumulative acute exacerbation-free rate in 1 year was 30.0%and 68.12%,respectively(F=11.1 P<0.05).Conclusion:The expression of irisin in serum of the COPD patients was lower than that in the health control group and its level increased after PR treatment.The reduction of irisin might be a poor prognostic indicator for acute exacerbation in patients with COPD.